Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix: review of the literature.
Neuroendocrine cell carcinoma of the cervix is a virulent tumor associated with an extremely poor prognosis. Even in clinical Stage I disease, there may be subclinical hematogenous and lymphatic metastases with frequent recurrences. Adjuvant postoperative external pelvic radiotherapy has been reported to offer some degree of local control; however, most patients succumb to distant disease. Following radical abdominal hysterectomy and pelvic lymphadenectomy, with confirmation of the neuroendocrine tumor by electron microscopy and immunohistochemical staining, two patients were given adjuvant systemic chemotherapy with concurrent pelvic radiotherapy, employing regimens with documented activity against small cell carcinoma of the lung of neuroendocrine origin. Despite severe myelotoxicity and persistent neuropathy, both patients are alive without clinical evidence of disease at 28+ and 47+ months.
O'Hanlan
K A
KA
Division of Gynecologic Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York 10461.
Goldberg
G L
GL
Jones
J G
JG
Runowicz
C D
CD
Ehrlich
L
L
Rodriguez-Rodriguez
L
L
D000328:Adult; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D004701:Endocrine Gland Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009423:Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D005047:Etoposide; D002945:Cisplatin